CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
US6787524B2 · kind B2 · utility
5Cited by
12References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 20, 2001 |
| Grant date | Sep 7, 2004 |
| Priority date | — |
| Expiry date | Jul 2, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55561
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a method of stimulating antibody-dependent cellular cytotoxicity to enhance the elimination of IgE-bearing B-cells comprising administering to a mammal an anti-IgE antibody, which binds to membrane bound IgE, but does not induce histamine release and administering an ISO to the mammal. The ISO may be a CpG containing oligonucleotide, or a modified CpG-containing oligonucleotide with an electron-withdrawing group at least at position C-5 of the cytosine in the CpG sequence. In addition, the method may include the administration of an allergen to improve desensitization therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.